Ultragenyx Pharmaceutical Dirección

Dirección controles de criterios 2/4

El CEO de Ultragenyx Pharmaceutical's es Emil Kakkis , nombrado en Apr 2010, tiene una permanencia de 13.92 años. compensación anual total es $12.14M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.29% de las acciones de la empresa, por valor de MX$2.30B. La antigüedad media del equipo directivo y de la junta directiva es de 8.7 años y 8 años, respectivamente.

Información clave

Emil Kakkis

Chief Executive Officer (CEO)

US$12.1m

Compensación total

Porcentaje del salario del CEO	6.6%
Permanencia del CEO	13.9yrs
Participación del CEO	3.3%
Permanencia media de la dirección	8.7yrs
Promedio de permanencia en la Junta Directiva	8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Emil Kakkis en comparación con los beneficios de Ultragenyx Pharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$607m
Sep 30 2023	n/a	n/a	-US$635m
Jun 30 2023	n/a	n/a	-US$721m
Mar 31 2023	n/a	n/a	-US$719m
Dec 31 2022	US$12m	US$796k	-US$707m
Sep 30 2022	n/a	n/a	-US$678m
Jun 30 2022	n/a	n/a	-US$506m
Mar 31 2022	n/a	n/a	-US$470m
Dec 31 2021	US$10m	US$769k	-US$454m
Sep 30 2021	n/a	n/a	-US$356m
Jun 30 2021	n/a	n/a	-US$351m
Mar 31 2021	n/a	n/a	-US$204m
Dec 31 2020	US$5m	US$759k	-US$187m
Sep 30 2020	n/a	n/a	-US$256m
Jun 30 2020	n/a	n/a	-US$301m
Mar 31 2020	n/a	n/a	-US$425m
Dec 31 2019	US$7m	US$714k	-US$403m
Sep 30 2019	n/a	n/a	-US$397m
Jun 30 2019	n/a	n/a	-US$371m
Mar 31 2019	n/a	n/a	-US$325m
Dec 31 2018	US$5m	US$680k	-US$198m
Sep 30 2018	n/a	n/a	-US$192m
Jun 30 2018	n/a	n/a	-US$183m
Mar 31 2018	n/a	n/a	-US$204m
Dec 31 2017	US$7m	US$638k	-US$302m

Compensación vs. Mercado: La compensación total de Emil($USD12.14M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD1.56M).

Compensación vs. Ingresos: La compensación de Emil ha aumentado mientras la empresa no es rentable.

CEO

Emil Kakkis (63 yo)

13.9yrs

Permanencia

US$12,140,330

Compensación

Dr. Emil D. Kakkis, MD, Ph D., is Venture Advisor of Forge Life Science Partners. He is Founder for Ultragenyx Pharmaceutical Inc. He has been the Chief Executive Officer and President of Ultragenyx Pharma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Emil Kakkis	Founder	13.9yrs	US$12.14m	3.29% $ 2.3b
John Pinion	Chief Quality Operations Officer & Executive VP of Translational Sciences	8.7yrs	US$3.71m	0.045% $ 31.3m
Erik Harris	Executive VP & Chief Commercial Officer	no data	US$3.75m	0.017% $ 12.0m
Howard Horn	Executive VP of Corporate Strategy & CFO	less than a year	sin datos	sin datos
Theodore Huizenga	Senior VP	10.2yrs	sin datos	0.016% $ 11.2m
Dennis Huang	Chief Technical Operations Off.	8.8yrs	US$4.24m	0.033% $ 23.4m
Danielle Keatley	Senior Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Karah Parschauer	Chief Legal Officer & Executive VP of Corporate Affairs	7.8yrs	US$2.04m	0.018% $ 12.6m
Ernie Meyer	Chief Human Resources Officer & Executive VP	3.5yrs	sin datos	sin datos
Thomas Kassberg	Chief Business Officer & Executive VP	12.3yrs	US$2.46m	0.25% $ 178.3m
Vimal Srivastava	Senior Vice President of Business Development & Alliance Management	6yrs	sin datos	sin datos
Aaron Olsen	Senior Vice President of Corporate Strategy & Finance	no data	sin datos	sin datos

8.7yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RARE * es experimentado (8.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Emil Kakkis	Founder	13.9yrs	US$12.14m	3.29% $ 2.3b
Daniel Welch	Independent Non-Executive Chairman	8.9yrs	US$499.44k	0.022% $ 15.1m
Lars Ekman	Independent Director	8yrs	US$463.44k	0.018% $ 12.3m
Matthew Fust	Independent Director	10.2yrs	US$478.19k	0.033% $ 23.0m
Shehnaaz Suliman	Independent Director	5.2yrs	US$466.44k	0.013% $ 9.3m
Deborah Dunsire	Independent Director	6.9yrs	US$462.19k	0.019% $ 13.5m
Corazon Sanders	Independent Director	2.8yrs	US$465.81k	0.0046% $ 3.3m
Michael Narachi	Independent Director	9.1yrs	US$481.31k	0.022% $ 15.1m
Amrit Ray	Independent Director	1.9yrs	US$1.24m	0.0061% $ 4.3m

8.0yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de RARE * se considera experimentada (8 años de antigüedad promedio).

Ultragenyx Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Ultragenyx Pharmaceutical Inc., Annual General Meeting, Jun 18, 2024

Ultragenyx Pharmaceutical Inc. Announces Appointment of Howard Horn as Chief Financial Officer, Effective October 16, 2023

Chief Medical Officer & Executive VP recently sold Mex$3.2m worth of stock

Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice President

Executive VP & CFO recently sold Mex$2.7m worth of stock

Executive VP & Chief Commercial Officer recently sold Mex$331k worth of stock

Recent updates

Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024

Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc., Annual General Meeting, Jun 18, 2024

Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Ultragenyx Pharmaceutical Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024

Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Mereo Biopharma Group plc Provides Update on Pipeline Progress and Corporate Developments

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$2.23 loss per share (vs US$3.50 loss in 3Q 2022)

Ultragenyx Pharmaceutical Inc. Announces Program and Pipeline Updates At Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (Oi), Angelman Syndrome (As) and Wilson Disease

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Launches Evkeeza (Enacumab for Injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Second quarter 2023 earnings released: US$2.25 loss per share (vs US$2.26 loss in 2Q 2022)

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2023

Ultragenyx Pharmaceutical Inc. Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Pharmaceutical Inc. Announces Appointment of Howard Horn as Chief Financial Officer, Effective October 16, 2023

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Small Cap Comp Value Index

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Ultragenyx Pharmaceutical Inc. Announces U.S. Food and Drug Administration Reviews and Agrees to Protocol Amendment to the Phase 1/2 Study of GTX-102

Ultragenyx Pharmaceutical Inc. Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2023 Annual Meeting

First quarter 2023 earnings released: US$2.33 loss per share (vs US$2.19 loss in 1Q 2022)

Ultragenyx Pharmaceutical Inc. Reaffirms Earning Guidance for the Full Year 2023

Chief Medical Officer & Executive VP recently sold Mex$3.2m worth of stock

Ultragenyx Pharmaceutical Inc. Reaffirms Full Year Earnings Guidance for the Year 2023

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Year 2022 and 2023

Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice President

Third quarter 2022 earnings released: US$3.50 loss per share (vs US$1.08 loss in 3Q 2021)

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2022

Executive VP & CFO recently sold Mex$2.7m worth of stock

Second quarter 2022 earnings released: US$2.26 loss per share (vs US$1.81 loss in 2Q 2021)

Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) acquired GeneTx Biotherapeutics LLC from Foundation for Angelman Syndrome Therapeutics and others for $190 million.

Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) acquired GeneTx Biotherapeutics LLC from Foundation for Angelman Syndrome Therapeutics and others for $190 million.

Executive VP & Chief Commercial Officer recently sold Mex$331k worth of stock

Ultragenyx Pharmaceutical Inc. Announces Positive Longer-Term Durability Data from Two Phase 1/2 Gene Therapy Studies

First quarter 2022 earnings released: US$2.19 loss per share (vs US$2.03 loss in 1Q 2021)

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Financial Year 2022

Ultragenyx Pharmaceutical Inc. Announces the Appointment of Amrit Ray to Board of Directors

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

Insufficient new directors

Ultragenyx Pharmaceutical Inc. Reaffirms Revenue Guidance for the Year 2022

Insufficient new directors

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Year 2022

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. Provides Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

Ultragenyx Pharmaceutical Inc. Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

Ultragenyx Pharmaceutical Inc. Announces New Long-Term Durability Data from Phase 1/2 Studies of DTX401 for Glycogen Storage Disease Type Ia and DTX301 for Ornithine Transcarbamylase Deficiency

Executive VP & CFO recently sold Mex$6.0m worth of stock

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S

Ultragenyx Pharmaceutical Inc. Announces Mepsevii® (Vestronidase Alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

Ultragenyx Canada Announces Health Canada Approval of Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults

Executive VP & Chief Commercial Officer recently sold Mex$686k worth of stock

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 2000 Growth Index

Executive VP & Chief Commercial Officer recently sold Mex$858k worth of stock

GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome

Forecast to breakeven in 2025

GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome

Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on Hela 3.0 Manufacturing Platform At American Society of Gene & Cell Therapy 2021 Annual Meeting

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2021

Insider recently sold Mex$7.7m worth of stock

Ultragenyx Announces FDA Clearance of Investigational New Drug (Ind) Application for Ux053, an Mrna for the Treatment of Glycogen Storage Disease Type Iii

Ultragenyx Pharmaceutical Inc. Announces Approval of Dojolvi (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Ultragenyx Pharmaceutical Inc. Announces Three Global, Pivotal Stage Gene Therapy Clinical Studies Expects in 2021

Ultragenyx Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for UX701, A New Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Pharmaceutical Inc. Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies